Maya Muhanna, Issac Lund, Mark Bromberg, Paul Wicks, Michael Benatar, Benjamin Barnes, Kaitlyn Pierce, Dylan Ratner, Andrew Brown, Tulio Bertorini, Paul Barkhaus, Greg Carter, Javier Mascias Cadavid, Christopher McDermott, Jonathan D Glass, Gary Pattee, Carmel Armon, Richard Bedlack, Xiaoyan Li
{"title":"ALSUntangled #73: Lion's Mane.","authors":"Maya Muhanna, Issac Lund, Mark Bromberg, Paul Wicks, Michael Benatar, Benjamin Barnes, Kaitlyn Pierce, Dylan Ratner, Andrew Brown, Tulio Bertorini, Paul Barkhaus, Greg Carter, Javier Mascias Cadavid, Christopher McDermott, Jonathan D Glass, Gary Pattee, Carmel Armon, Richard Bedlack, Xiaoyan Li","doi":"10.1080/21678421.2023.2296557","DOIUrl":null,"url":null,"abstract":"<p><p>Lion's Mane (<i>Hericium erinaceus)</i> has historically been used as traditional medicine in Asia and Europe for its potential benefits in fighting infection and cancer. It has gained interest in the neurodegenerative disease field because of its mechanisms of action; these include anti-inflammation, neuroprotection, and promoting neurite growth demonstrated in various cell and animal models. A very small, double-blind, placebo-controlled trial in patients with mild cognitive impairment showed a temporary improvement in cognitive function; this finding has yet to be replicated. However, there have been no studies in ALS cell or animal models or in humans with ALS. Lion's Mane appears safe and inexpensive when consumed in powder or capsule, but one anaphylactic case was reported after a patient consumed fresh Lion's Mane mushroom. Currently, we do not have enough information to support the use of Lion's Mane for treating ALS. We support further research in ALS disease models and clinical trials to study its efficacy.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2023.2296557","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Lion's Mane (Hericium erinaceus) has historically been used as traditional medicine in Asia and Europe for its potential benefits in fighting infection and cancer. It has gained interest in the neurodegenerative disease field because of its mechanisms of action; these include anti-inflammation, neuroprotection, and promoting neurite growth demonstrated in various cell and animal models. A very small, double-blind, placebo-controlled trial in patients with mild cognitive impairment showed a temporary improvement in cognitive function; this finding has yet to be replicated. However, there have been no studies in ALS cell or animal models or in humans with ALS. Lion's Mane appears safe and inexpensive when consumed in powder or capsule, but one anaphylactic case was reported after a patient consumed fresh Lion's Mane mushroom. Currently, we do not have enough information to support the use of Lion's Mane for treating ALS. We support further research in ALS disease models and clinical trials to study its efficacy.
狮鬃草（Hericium erinaceus）在亚洲和欧洲历来被用作传统药物，因为它具有抗感染和抗癌的潜在功效。在神经退行性疾病领域，狮鬃草的作用机制引起了人们的兴趣，其中包括在各种细胞和动物模型中证实的抗炎、神经保护和促进神经元生长。一项针对轻度认知障碍患者的小型双盲安慰剂对照试验显示，该药物可暂时改善患者的认知功能；这一发现尚未得到证实。不过，目前还没有对 ALS 细胞或动物模型或 ALS 患者进行研究。以粉末或胶囊形式食用的狮鬃蘑菇似乎安全且价格低廉，但有报告称一名患者在食用新鲜狮鬃蘑菇后出现过敏反应。目前，我们还没有足够的信息来支持使用狮鬃菇治疗 ALS。我们支持在 ALS 疾病模型和临床试验中进一步研究其疗效。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
